(Q44124042)

30 November 2017

0 references

1 reference

title

The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors (English)

1 reference

30 November 2017

1 reference

1

Vibeke Strand

1 reference

30 November 2017

Marc C Hochberg

2

1 reference

30 November 2017

publication date

1 August 2002

1 reference

30 November 2017

published in

Arthritis & Rheumatology

1 reference

30 November 2017

volume

47

1 reference

30 November 2017

issue

4

1 reference

30 November 2017

page(s)

349-355

1 reference

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

30 November 2017

cites work

1 reference

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection

21 January 2018

1 reference

Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease.

21 January 2018

1 reference

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

21 January 2018

1 reference

Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits

21 January 2018

1 reference

The coxibs, selective inhibitors of cyclooxygenase-2.

21 January 2018

1 reference

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease.

21 January 2018

1 reference

Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial

21 January 2018

1 reference

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

21 January 2018

1 reference

Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project

21 January 2018

1 reference

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

21 January 2018

1 reference

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

21 January 2018

1 reference

Association between naproxen use and protection against acute myocardial infarction

21 January 2018

1 reference

Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis

21 January 2018

1 reference

No reduction in cardiovascular risk with NSAIDs-including aspirin?

21 January 2018

1 reference

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

21 January 2018

1 reference

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

21 January 2018

1 reference

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac

21 January 2018

1 reference

Risk of cardiovascular events associated with selective COX-2 inhibitors

21 January 2018

1 reference

Final report on the aspirin component of the ongoing Physicians' Health Study

21 January 2018

1 reference

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

Indobufen: an updated review of its use in the management of atherothrombosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.10560

1 reference

30 November 2017

1 reference